The Novo Nordisk Foundation and WHO are deepening the partnership, adopting a more strategic approach through the signature of a framework agreement that will enable the two organisations to accelerate progress by working together, they state. This includes opportunities to collaborate on the promotion, provision and protection of health, addressing the growing burden of non-communicable diseases (NCDs) with emphasis on cardiometabolic diseases; critical gaps in the health workforce; inequity in access to quality NCD services as well as antimicrobial resistance.

For several years, the Novo Nordisk Foundation and WHO have supported WHO’s emergency health response operations, in additional to supporting WHO’s work on NCDs in emergencies. The strategic framework agreement for the coming four years is an expansion of this engagement.

WHO plays a unique role in the global health ecosystem, providing normative guidance, monitoring diseases, building country capacity for resilient health systems and supporting learning and evidence.

“We are thrilled to enter into this agreement with WHO, which will strengthen our partnership and serve our common mission of advancing global health,” says Mads Krogsgaard Thomsen, CEO of the Novo Nordisk Foundation. “WHO plays a unique role in the global health ecosystem, providing normative guidance, monitoring diseases, building country capacity for resilient health systems and supporting learning and evidence.”